The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The ongoing shortage of liraglutide injection and other GLP-1 medications prompted the FDA to prioritize the generic drug applications for these medications in order to improve patient access.

“These findings suggest that BMI and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...